HXBM OTC
Helix BioMedix, Inc.
1W: -34.2%
1M: -45.2%
3M: +83.8%
YTD: +64.5%
1Y: -6.0%
3Y: -85.0%
5Y: -86.9%
$3.29
-1.11 (-25.28%)
Weekly Expected Move ±43.7%
$0
$2
$3
$5
$6
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$807K
+0.4% ▲
5Y CAGR: -15.2%
Gross Profit
$802K
+0.5% ▲
5Y CAGR: -14.3%
Operating Income
-$596K
+44.0% ▲
Net Income
-$552K
+43.9% ▲
EPS (Diluted)
$-2.45
+43.9% ▲
EBITDA
-$591K
+39.5% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2M | $2M | $998K | $804K | $807K |
| YoY Growth | +29.3% | -26.1% | -43.1% | -19.4% | +0.4% |
| Cost of Revenue | $444K | $16K | $10K | $6K | $5K |
| Gross Profit | $2M | $2M | $988K | $798K | $802K |
| Gross Margin | 81.3% | 99.1% | 99.0% | 99.2% | 99.4% |
| R&D Expenses | $1M | $892K | $317K | $511K | $177K |
| SG&A Expenses | $2M | $2M | $2M | $1M | $1M |
| Operating Expenses | $3M | $3M | $2M | $2M | $1M |
| Operating Income | -$1M | -$1M | -$984K | -$1M | -$596K |
| Operating Margin | -55.8% | -61.5% | -98.6% | -132.3% | -73.8% |
| Interest Expense | $352K | $0 | $0 | $0 | $0 |
| Income Before Tax | -$1M | -$1M | -$1M | -$982K | -$552K |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$1M | -$1M | -$1M | -$982K | -$552K |
| Net Margin | -57.3% | -67.9% | -105.8% | -122.1% | -68.3% |
| EPS (Diluted) | $-6.05 | $-5.31 | $-4.70 | $-4.37 | $-2.45 |
| EBITDA | -$995K | -$1M | -$1M | -$976K | -$591K |
| Shares Outstanding | 224708 | 224707 | 224707 | 224707 | 224707 |